Clinical evaluation of the safety and efficacy of a timosaponin A‐III‐based antiwrinkle agent against skin aging

• DOI: 10.1111/jocd.13035
• Publication Date: 2019-06-19T09:55:14Z
• Authors: A‐Rang Im; Young Kyoung Seo; Se Hee Cho; Kyeong Hee O; Ki Mo Kim; Sungwook Chae
• Keywords: HaCaT; Photoaging; Wrinkle; Human skin; Skin Aging

Abstract Background Timosaponin A‐III (TA‐III) is known to exist in the medicinal herb of Anemarrhena asphodeloides as one major chemical components. Aims The photoprotective properties TA‐III on UVB‐exposed HaCaT cells were evaluated antiwrinkle effects and skin safety terms clinical trial. Methods level matrix metalloproteinase (MMP)‐1, tissue inhibitor metalloproteinases (TIMPs), pro‐inflammatory cytokines measured following UVB irradiation. To evaluate an agent containing 0.25% for use human skin. Female subjects (n = 21) between ages 43 55 who met criteria subject selection selected. They beginning form or had already formed wrinkles. Results irradiation increased MMP‐1 expression cytokines. These increases attenuated by pretreatment cells. We found that ameliorated wrinkling. A comparison groups showed wrinkle parameters significantly reduced after 12 weeks product ( P < 0.05). According result, no dermatological toxicity was participants. Conclusions In conclusion, could provide protection against photoaging daily application signs facial aging limiting formation.